{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["analysis", "chemistry", "isolation", "pharmacology", "\u03948-THC"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38542886", "DateCompleted": {"Year": "2024", "Month": "03", "Day": "29"}, "DateRevised": {"Year": "2024", "Month": "03", "Day": "30"}, "Article": {"Language": ["eng"], "ELocationID": ["1249", "10.3390/molecules29061249"], "ArticleDate": [{"Year": "2024", "Month": "03", "Day": "11"}], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "29", "Issue": "6", "PubDate": {"Year": "2024", "Month": "Mar", "Day": "11"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Chemistry and Pharmacology of Delta-8-Tetrahydrocannabinol.", "Abstract": {"AbstractText": ["<i>Cannabis sativa</i> is one of the oldest plants utilized by humans for both economic and medical purposes. Although the use of cannabis started millennia ago in the Eastern hemisphere, its use has moved and flourished in the Western nations in more recent centuries. <i>C. sativa</i> is the source of psychoactive cannabinoids that are consumed as recreational drugs worldwide. The C21 aromatic hydrocarbons are restricted in their natural occurrence to cannabis (with a few exceptions). Delta-9-tetrahydrocannabinol (\u0394<sup>9</sup>-THC) is the main psychoactive component in cannabis, with many pharmacological effects and various approved medical applications. However, a wide range of side effects are associated with the use of \u0394<sup>9</sup>-THC, limiting its medical use. In 1966, another psychoactive cannabinoid, Delta-8-tetrahydrocannabinol (\u0394<sup>8</sup>-THC) was isolated from marijuana grown in Maryland but in very low yield. \u0394<sup>8</sup>-THC is gaining increased popularity due to its better stability and easier synthetic manufacturing procedures compared to \u0394<sup>9</sup>-THC. The passing of the U.S. Farm Bill in 2018 led to an increase in the sale of \u0394<sup>8</sup>-THC in the United States. The marketed products contain \u0394<sup>8</sup>-THC from synthetic sources. In this review, methods of extraction, purification, and structure elucidation of \u0394<sup>8</sup>-THC will be presented. The issue of whether \u0394<sup>8</sup>-THC is a natural compound or an artifact will be discussed, and the different strategies for its chemical synthesis will be presented. \u0394<sup>8</sup>-THC of synthetic origin is expected to contain some impurities due to residual amounts of starting materials and reagents, as well as side products of the reactions. The various methods of analysis and detection of impurities present in the marketed products will be discussed. The pharmacological effects of \u0394<sup>8</sup>-THC, including its interaction with CB1 and CB2 cannabinoid receptors in comparison with \u0394<sup>9</sup>-THC, will be reviewed."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Pharmacognosy Department, Faculty of Pharmacy, Alexandria University, Alexandria 21215, Egypt."}], "LastName": "Abdel-Kader", "ForeName": "Maged S", "Initials": "MS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy Department, Faculty of Pharmacy, Alexandria University, Alexandria 21215, Egypt."}, {"Identifier": [], "Affiliation": "National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS 38677, USA."}], "LastName": "Radwan", "ForeName": "Mohamed M", "Initials": "MM"}, {"Identifier": ["0000-0001-8566-1980"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": ["0000-0002-6955-2263"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Hazekamp Herbal Consulting, 6420 Leiden, The Netherlands."}], "LastName": "Hazekamp", "ForeName": "Arno", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS 38677, USA."}, {"Identifier": [], "Affiliation": "Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS 38677, USA."}], "LastName": "ElSohly", "ForeName": "Mahmoud A", "Initials": "MA"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "5957-75-5", "NameOfSubstance": "delta-8-tetrahydrocannabinol"}, {"RegistryNumber": "7J8897W37S", "NameOfSubstance": "Dronabinol"}, {"RegistryNumber": "0", "NameOfSubstance": "Cannabinoids"}, {"RegistryNumber": "0", "NameOfSubstance": "Cannabinoid Receptor Agonists"}, {"RegistryNumber": "0", "NameOfSubstance": "Hallucinogens"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology", "analogs & derivatives"], "DescriptorName": "Dronabinol"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Cannabinoids"}, {"QualifierName": [], "DescriptorName": "Cannabis"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Cannabinoid Receptor Agonists"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Hallucinogens"}], "CoiStatement": "Author Arno Hazekamp was employed by the company Hazekamp Herbal Consulting. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Kriese U., Schumann E., Weber W., Beyer M., Br\u00fchl L., Matth\u00e4us Oil content, tocopherol composition and fatty acid patterns of the seeds of 51 Cannabis sativa L. genotypes. Euphytica. 2004;137:339\u2013351. doi: 10.1023/B:EUPH.0000040473.23941.76.", "ArticleIdList": ["10.1023/B:EUPH.0000040473.23941.76"]}, {"Citation": "Doyle E., Spence A. Cannabis as a medicine? Br. J. Anaesth. 1995;74:359\u2013361.", "ArticleIdList": ["7734249"]}, {"Citation": "Zuardi A.W. History of cannabis as a medicine: A review. Braz. J. Psychiatry. 2006;28:153\u2013157. doi: 10.1590/S1516-44462006000200015.", "ArticleIdList": ["10.1590/S1516-44462006000200015", "16810401"]}, {"Citation": "Crocq M.-A. History of cannabis and the endocannabinoid system. Dialogues Clin. Neurosci. 2020;22:223\u2013228. doi: 10.31887/DCNS.2020.22.3/mcrocq.", "ArticleIdList": ["10.31887/DCNS.2020.22.3/mcrocq", "PMC7605027", "33162765"]}, {"Citation": "Gaoni Y., Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 1964;86:1646\u20131647. doi: 10.1021/ja01062a046.", "ArticleIdList": ["10.1021/ja01062a046"]}, {"Citation": "ElSohly M.A., Radwan M.M., Gul W., Chandra S., Galal A. Phytochemistry of Cannabis sativa L. In: Kinghorn A.D., Falk H., Gibbons S., Kobayashi J.I., editors. Phytocannabinoids: Unraveling the Complex Chemistry and Pharmacology of Cannabis sativa. Springer International Publishing; Cham, Switzerland: 2017. pp. 1\u201336."}, {"Citation": "Turner C.E., Elsohly M.A., Boeren E.G. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J. Nat. Prod. 1980;43:169\u2013234. doi: 10.1021/np50008a001.", "ArticleIdList": ["10.1021/np50008a001", "6991645"]}, {"Citation": "Radwan M.M., Chandra S., Gul S., ElSohly M.A. Cannabinoids, phenolics, terpenes and alkaloids of cannabis. Molecules. 2021;26:2774. doi: 10.3390/molecules26092774.", "ArticleIdList": ["10.3390/molecules26092774", "PMC8125862", "34066753"]}, {"Citation": "Pertwee R.G. Pharmacological Actions of Cannabinoids. In: Pertwee R.G., editor. Cannabinoids. Springer; Berlin/Heidelberg, Germany: 2005. pp. 1\u201351.", "ArticleIdList": ["16596770"]}, {"Citation": "Maccarrone M. Missing pieces to the endocannabinoid puzzle. Trends Mol. Med. 2020;26:263\u2013272. doi: 10.1016/j.molmed.2019.11.002.", "ArticleIdList": ["10.1016/j.molmed.2019.11.002", "31822395"]}, {"Citation": "Alves P., Amaral C., Teixeira N., Correia-da-Silva G. Cannabis sativa: Much more beyond \u03949-tetrahydrocannabinol. Pharmacol. Res. 2020;157:104822. doi: 10.1016/j.phrs.2020.104822.", "ArticleIdList": ["10.1016/j.phrs.2020.104822", "32335286"]}, {"Citation": "Preet A., Ganju R., Groopman J. \u03949-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene. 2008;27:339\u2013346. doi: 10.1038/sj.onc.1210641.", "ArticleIdList": ["10.1038/sj.onc.1210641", "17621270"]}, {"Citation": "Caffarel M.M., Andradas C., Mira E., P\u00e9rez-G\u00f3mez E., Cerutti C., Moreno-Bueno G., Flores J.M., Garc\u00eda-Real I., Palacios J., Ma\u00f1es S. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol. Cancer. 2010;9:196. doi: 10.1186/1476-4598-9-196.", "ArticleIdList": ["10.1186/1476-4598-9-196", "PMC2917429", "20649976"]}, {"Citation": "Laezza C., Pagano C., Navarra G., Pastorino O., Proto M.C., Fiore D., Piscopo C., Gazzerro P., Bifulco M. The endocannabinoid system: A target for cancer treatment. Int. J. Mol. Sci. 2020;21:747. doi: 10.3390/ijms21030747.", "ArticleIdList": ["10.3390/ijms21030747", "PMC7037210", "31979368"]}, {"Citation": "Pagano C., Navarra G., Coppola L., Bifulco M., Laezza C. Molecular mechanism of cannabinoids in cancer progression. Int. J. Mol. Sci. 2021;22:3680. doi: 10.3390/ijms22073680.", "ArticleIdList": ["10.3390/ijms22073680", "PMC8037087", "33916164"]}, {"Citation": "Institute of Medicine (US) Development of Cannabinoid Drugs. In: Joy J.E., Watson S.J. Jr., Benson J.A. Jr., editors. Marijuana and Medicine: Assessing the Science Base. National Academies Press; Washington, DC, USA: 1999.", "ArticleIdList": ["25101425"]}, {"Citation": "Zeiger J.S., Haberstick B.C., Corley R.P., Ehringer M.A., Crowley T.J., Hewitt J.K., Hopfer C.J., Stallings M.C., Young S.E., Rhee S.H. Subjective effects to marijuana associated with marijuana use in community and clinical subjects. Drug Alcohol Depend. 2010;109:161\u2013166. doi: 10.1016/j.drugalcdep.2009.12.026.", "ArticleIdList": ["10.1016/j.drugalcdep.2009.12.026", "PMC3000695", "20149559"]}, {"Citation": "Crean R.D., Crane N.A., Mason B.J. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J. Addict. Med. 2011;5:1\u20138. doi: 10.1097/ADM.0b013e31820c23fa.", "ArticleIdList": ["10.1097/ADM.0b013e31820c23fa", "PMC3037578", "21321675"]}, {"Citation": "Curran V.H., Brignell C., Fletcher S., Middleton P., Henry J. Cognitive and subjective dose-response effects of acute oral \u03949-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology. 2002;164:61\u201370. doi: 10.1007/s00213-002-1169-0.", "ArticleIdList": ["10.1007/s00213-002-1169-0", "12373420"]}, {"Citation": "Fern\u00e1ndez-Serrano M.J., P\u00e9rez-Garc\u00eda M., Verdejo-Garc\u00eda A. What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance? Neurosci. Biobehav. Rev. 2011;35:377\u2013406. doi: 10.1016/j.neubiorev.2010.04.008.", "ArticleIdList": ["10.1016/j.neubiorev.2010.04.008", "20451551"]}, {"Citation": "D\u2019Souza D.C., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.-t., Braley G., Gueorguieva R., Krystal J.H. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology. 2004;29:1558\u20131572. doi: 10.1038/sj.npp.1300496.", "ArticleIdList": ["10.1038/sj.npp.1300496", "15173844"]}, {"Citation": "Murray R.M., Di Forti M. Cannabis and psychosis: What degree of proof do we require? Biol. Psychiatry. 2016;79:514\u2013515. doi: 10.1016/j.biopsych.2016.02.005.", "ArticleIdList": ["10.1016/j.biopsych.2016.02.005", "26970362"]}, {"Citation": "Grotenhermen F. Review of unwanted actions of cannabis and THC. In: Grotenhermen F., Russo E.B., editors. Cannabis and Cannabinoids. Pharmacology, Toxicology, and Therapeutic Potential. Haworth Press; New York, NY, USA: 2002. pp. 233\u2013248."}, {"Citation": "Leweke F.M. Acute effects of cannabis and the cannabinoids. In: Russo E.B., Grotenhermen F., editors. Cannabis and Cannabinoids. Pharmacology, Toxicology and Therapeutic Potential. The Haworth Integrative Healing Press; New York, NY, USA: 2002. pp. 249\u2013256."}, {"Citation": "Hively R.L., Mosher W.A., Hoffmann F.W. Isolation of trans-\u03946-tetrahydrocannabinol from marijuana. J. Am. Chem. Soc. 1966;88:1832\u20131833. doi: 10.1021/ja00960a056.", "ArticleIdList": ["10.1021/ja00960a056", "5942992"]}, {"Citation": "Krejc\u00ed Z., \u0160antav\u00fd F. Isolation of two new cannabinoid acids from Cannabis sativa L. of Czechoslovak origin. Acta Univ. Olomuc. Fac. Med. 1975;74:161\u2013166."}, {"Citation": "Radwan M.M., ElSohly M.A., El-Alfy A.T., Ahmed S.A., Slade D., Husni A.S., Manly S.P., Wilson L., Seale S., Cutler S.J. Isolation and pharmacological evaluation of minor cannabinoids from high-potency Cannabis sativa. J. Nat. Prod. 2015;78:1271\u20131276. doi: 10.1021/acs.jnatprod.5b00065.", "ArticleIdList": ["10.1021/acs.jnatprod.5b00065", "PMC4880513", "26000707"]}, {"Citation": "Ahmed S.A., Ross S.A., Slade D., Radwan M.M., Khan I.A., ElSohly M.A. Minor oxygenated cannabinoids from high potency Cannabis sativa L. Phytochemistry. 2015;117:194\u2013199. doi: 10.1016/j.phytochem.2015.04.007.", "ArticleIdList": ["10.1016/j.phytochem.2015.04.007", "PMC4883105", "26093324"]}, {"Citation": "Hanu\u0161 L.O., Meyer S.M., Mu\u00f1oz E., Taglialatela-Scafati O., Appendino G. Phytocannabinoids: A unified critical inventory. Nat. Prod. Rep. 2016;33:1357\u20131392. doi: 10.1039/C6NP00074F.", "ArticleIdList": ["10.1039/C6NP00074F", "27722705"]}, {"Citation": "Mechoulam R., Braun P., Gaoni Y. Stereospecific synthesis of (-)-.DELTA.1- and (-)-.DELTA.1(6)-tetrahydrocannabinols. J. Am. Chem. Soc. 1967;89:4552\u20134554. doi: 10.1021/ja00993a072.", "ArticleIdList": ["10.1021/ja00993a072", "6046550"]}, {"Citation": "Zlas J., Stark H., Seligman J., Levy R., Werker E., Breuer A., Mechoulam R. Early medical use of cannabis. Nature. 1993;363:215. doi: 10.1038/363215a0.", "ArticleIdList": ["10.1038/363215a0", "8387642"]}, {"Citation": "Husni A.S., McCurdy C.R., Radwan M.M., Ahmed S.A., Slade D., Ross S.A., ElSohly M.A., Cutler S.J. Evaluation of phytocannabinoids from high-potency Cannabis sativa using in vitro bioassays to determine structure\u2013activity relationships for cannabinoid receptor 1 and cannabinoid receptor 2. Med. Chem. Res. 2014;23:4295\u20134300. doi: 10.1007/s00044-014-0972-6.", "ArticleIdList": ["10.1007/s00044-014-0972-6", "PMC4235762", "25419092"]}, {"Citation": "Hollister L.E., Gillespie H.K. Delta-8-and delta-9-tetrahydrocannabinol; Comparison in man by oral and intravenous administration. Clin. Pharmacol. Ther. 1973;14:353\u2013357. doi: 10.1002/cpt1973143353.", "ArticleIdList": ["10.1002/cpt1973143353", "4698563"]}, {"Citation": "Stern E., Lambert D.M. Medicinal chemistry endeavors around the phytocannabinoids. Chem. Biodivers. 2007;4:1707\u20131728. doi: 10.1002/cbdv.200790149.", "ArticleIdList": ["10.1002/cbdv.200790149", "17712816"]}, {"Citation": "Leas E.C., Nobles A.L., Shi Y., Hendrickson E. Public interest in \u2206 8-Tetrahydrocannabinol (delta-8-THC) increased in US states that restricted\u2206 9-Tetrahydrocannabinol (delta-9-THC) use. Int. J. Drug Policy. 2022;101:103557. doi: 10.1016/j.drugpo.2021.103557.", "ArticleIdList": ["10.1016/j.drugpo.2021.103557", "PMC9126323", "34952279"]}, {"Citation": "Babalonis S., Raup-Konsavage W.M., Akpunonu P.D., Balla A., Vrana K.E. \u03948-THC: Legal status, widespread availability, and safety concerns. Cannabis Cannabinoid Res. 2021;6:362\u2013365.", "ArticleIdList": ["PMC8664123", "34662224"]}, {"Citation": "Radwan M.M., Wanas A.S., Gul W., Ibrahim E.A., ElSohly M.A. Isolation and Characterization of Impurities in Commercially Marketed \u03948-THC Products. J. Nat. Prod. 2023;86:822\u2013829. doi: 10.1021/acs.jnatprod.2c01008.", "ArticleIdList": ["10.1021/acs.jnatprod.2c01008", "36827690"]}, {"Citation": "The U.S. Food and Drug Administration  5 Things to Know about Delta-8-Tetrahydrocannabinol-Delta-8-THC.  [(accessed on 19 November 2023)]; Available online:  https://www.fda.gov/consumers/consumer-updates/5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc."}, {"Citation": "Adams R. Marihuana: Harvey lecture, February 19, 1942. Bull. N. Y. Acad. Med. 1942;18:705.", "ArticleIdList": ["PMC1933888", "19312292"]}, {"Citation": "Pars H.G., Razdan R.K. Tetrahydrocannabinols and synthetic analogs. Ann. N. Y. Acad. Sci. 1971;191:15\u201322. doi: 10.1111/j.1749-6632.1971.tb13983.x.", "ArticleIdList": ["10.1111/j.1749-6632.1971.tb13983.x"]}, {"Citation": "Turner C.E., Hadley K.W., Fetterman P.S., Doorenbos N.J., Quimby M.W., Waller C. Constituents of Cannabis sativa L. IV: Stability of cannabinoids in stored plant material. J. Pharm. Sci. 1973;62:1601\u20131605. doi: 10.1002/jps.2600621005.", "ArticleIdList": ["10.1002/jps.2600621005", "4752104"]}, {"Citation": "Turner C., Hadley K.W., Davis K.H. Constituents of Cannabis sativa L. V: Stability of an analytical sample extracted with chloroform. Acta Pharm. Jucoslavica. 1973;23:89\u201394."}, {"Citation": "Rzeppa S., Gro\u00dfe J., Rautenberg C., Thieme D., Lepp T., Vallim\u00e4e H., Keiler A.M. Emergence of the less common cannabinoid \u03948-Tetrahydrocannabinol in a doping sample. Drug Test. Anal. 2021;13:1936\u20131943. doi: 10.1002/dta.3159.", "ArticleIdList": ["10.1002/dta.3159", "34494719"]}, {"Citation": "Chan-Hosokawa A., Nguyen L., Lattanzio N., Adams W.R. Emergence of delta-8 tetrahydrocannabinol in DUID investigation casework: Method development, validation and application. J. Anal. Toxicol. 2022;46:1\u20139. doi: 10.1093/jat/bkab029.", "ArticleIdList": ["10.1093/jat/bkab029", "33754645"]}, {"Citation": "Leas E.C. The Hemp Loophole: A Need to Clarify the Legality of Delta-8-THC and Other Hemp-Derived Tetrahydrocannabinol Compounds. American Public Health Association; Washington, DC, USA: 2021. pp. 1927\u20131931.", "ArticleIdList": ["PMC8630489", "34618542"]}, {"Citation": "Marzullo P., Foschi F., Coppini D.A., Fanchini F., Magnani L., Rusconi S., Luzzani M., Passarella D. Cannabidiol as the substrate in acid-catalyzed intramolecular cyclization. J. Nat. Prod. 2020;83:2894\u20132901. doi: 10.1021/acs.jnatprod.0c00436.", "ArticleIdList": ["10.1021/acs.jnatprod.0c00436", "PMC8011986", "32991167"]}, {"Citation": "Gaoni Y., Mechoulam R. Hashish\u2014VII: The isomerization of cannabidiol to tetrahydrocannabinols. Tetrahedron. 1966;22:1481\u20131488. doi: 10.1016/S0040-4020(01)99446-3.", "ArticleIdList": ["10.1016/S0040-4020(01)99446-3"]}, {"Citation": "Razdan R.K. Chemistry and structure-activity relationships of cannabinoids: An overview. In: Agurell S., Dewey W.L., Willette R.E., editors. The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects. Academic Press Inc.; Orlando, FL, USA: 1984. pp. 63\u201378."}, {"Citation": "Pertwee R.G., Cascio M.G. Known Pharmacological Actions of Delta-9-tetrahydrocannabinol and of Four Other Chemical Constituents of Cannabis That Activate Cannabinoid Receptors. Volume 115 Oxford University Press; Oxford, UK: 2014."}, {"Citation": "Masoud A., Wingard D. High performance liquid chromatography with electrochemical detection. 1: Separation of Cannabis constituents and quantitation of \u03949 tetrahydrocannabinol. J. High Resolut. Chromatogr. 1979;2:118\u2013122. doi: 10.1002/jhrc.1240020304.", "ArticleIdList": ["10.1002/jhrc.1240020304"]}, {"Citation": "Correia B., Ahmad S.M., Quintas A. Determination of phytocannabinoids in cannabis samples by ultrasound-assisted solid-liquid extraction and high-performance liquid chromatography with diode array detector analysis. J. Chromatogr. A. 2023;1705:464191. doi: 10.1016/j.chroma.2023.464191.", "ArticleIdList": ["10.1016/j.chroma.2023.464191", "37454455"]}, {"Citation": "Elhendawy M.A., Radwan M.M., Ibrahim E.A., Wanas A.S., Chandra S., Godfrey M., ElSohly M.A. Validation and Quantitation of Fifteen Cannabinoids in Cannabis and Marketed Products Using High-Performance Liquid Chromatography-Ultraviolet/Photodiode Array Method. Cannabis Cannabinoid Res. 2023 doi: 10.1089/can.2022.0335. ahead of print .", "ArticleIdList": ["10.1089/can.2022.0335", "37797227"]}, {"Citation": "Duffy B.C., Li L., Lu S., Dittmar M.A., Delaney-Baldwin E., Durocher L.A., Spink D.C. Chemotyping of\u2206 8-THC-Containing e-Liquids Analyzed during the 2019\u20132020 New York State EVALI Investigation. J. Anal. Toxicol. 2022;46:743\u2013749. doi: 10.1093/jat/bkab107.", "ArticleIdList": ["10.1093/jat/bkab107", "34665862"]}, {"Citation": "Wang Y.-H., Avula B., ElSohly M.A., Radwan M.M., Wang M., Wanas A.S., Mehmedic Z., Khan I.A. Quantitative determination of \u03949-THC, CBG, CBD, their acid precursors and five other neutral cannabinoids by UHPLC-UV-MS. Planta Medica. 2018;84:260\u2013266. doi: 10.1055/s-0043-124873.", "ArticleIdList": ["10.1055/s-0043-124873", "29262425"]}, {"Citation": "Kri\u017eman M. A simplified approach for isocratic HPLC analysis of cannabinoids by fine tuning chromatographic selectivity. Eur. Food Res. Technol. 2020;246:315\u2013322. doi: 10.1007/s00217-019-03344-7.", "ArticleIdList": ["10.1007/s00217-019-03344-7"]}, {"Citation": "Song L., Carlson S., Valenzuela G., Chao M., Pathipaka S.B. Development of a validated method for rapid quantification of up to sixteen cannabinoids using ultra-high-performance liquid chromatography diode-array detector with optional electrospray ionization time-of-flight mass spectrometry detection. J. Chromatogr. A. 2022;1670:462953. doi: 10.1016/j.chroma.2022.462953.", "ArticleIdList": ["10.1016/j.chroma.2022.462953", "35334372"]}, {"Citation": "Madden O., Walshe J., Kishore Patnala P., Barron J., Meaney C., Murray P. Phytocannabinoids-An Overview of the Analytical Methodologies for Detection and Quantification of Therapeutically and Recreationally Relevant Cannabis Compounds. Crit. Rev. Anal. Chem. 2023;53:211\u2013231. doi: 10.1080/10408347.2021.1949694.", "ArticleIdList": ["10.1080/10408347.2021.1949694", "34328047"]}, {"Citation": "Christinat N., Savoy M.-C., Mottier P. Development, validation and application of a LC-MS/MS method for quantification of 15 cannabinoids in food. Food Chem. 2020;318:126469. doi: 10.1016/j.foodchem.2020.126469.", "ArticleIdList": ["10.1016/j.foodchem.2020.126469", "32143130"]}, {"Citation": "Berman P., Futoran K., Lewitus G.M., Mukha D., Benami M., Shlomi T., Meiri D. A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis. Sci. Rep. 2018;8:14280. doi: 10.1038/s41598-018-32651-4.", "ArticleIdList": ["10.1038/s41598-018-32651-4", "PMC6155167", "30250104"]}, {"Citation": "Trofin I.G., Vlad C.C., Noja V.V., Dabija G. Identification and characterization of special types of herbal cannabis. UPB Bul. Stiintific Ser. B Chem. Mater. Sci. 2012;74:119\u2013130."}, {"Citation": "United States Congress  H.R.2. Agriculture Improvement Act of 2018; Proceedings of the 115th United States Congress; Washington, DC, USA. 20 December 2018;  [(accessed on 6 December 2023)].  Available online:  https://www.congress.gov/bill/115th-congress/house-bill/2."}, {"Citation": "Drug Enforcement Administration (DEA), Department of Justice  Implementation of the Agriculture Improvement Act of 2018.  [(accessed on 20 November 2023)]; Available online:  https://www.federalregister.gov/documents/2020/08/21/2020-17356/implementation-of-the-agriculture-improvement-act-of-2018."}, {"Citation": "Razdan R.K., Dalzell H.C., Handrick G.R. Hashish. X. Simple one-step synthesis of (-)-.DELTA.1-tetrahydrocannabinol (THC) from p-mentha-2,8-dien-1-ol and olivetol. J. Am. Chem. Soc. 1974;96:5860\u20135865. doi: 10.1021/ja00825a026.", "ArticleIdList": ["10.1021/ja00825a026", "4413630"]}, {"Citation": "Malkov A.V., Ko\u010dovsk\u00fd P. Tetrahydrocannabinol revisited: Synthetic approaches utilizing molybdenum catalysts. Collect. Czechoslov. Chem. Commun. 2001;66:1257\u20131268. doi: 10.1135/cccc20011257.", "ArticleIdList": ["10.1135/cccc20011257"]}, {"Citation": "Meehan-Atrash J., Rahman I. Novel \u03948-tetrahydrocannabinol vaporizers contain unlabeled adulterants, unintended byproducts of chemical synthesis, and heavy metals. Chem. Res. Toxicol. 2021;35:73\u201376. doi: 10.1021/acs.chemrestox.1c00388.", "ArticleIdList": ["10.1021/acs.chemrestox.1c00388", "PMC8898185", "34889611"]}, {"Citation": "Ray C.L., Bylo M.P., Pescaglia J., Gawenis J.A., Greenlief C.M. Delta-8 tetrahydrocannabinol product impurities. Molecules. 2022;27:6924. doi: 10.3390/molecules27206924.", "ArticleIdList": ["10.3390/molecules27206924", "PMC9608670", "36296514"]}, {"Citation": "Ciolino L.A., Ranieri T.L., Brueggemeyer J.L., Taylor A.M., Mohrhaus A.S. EVALI vaping liquids part 1: GC-MS cannabinoids profiles and identification of unnatural THC isomers. Front. Chem. 2021;9:746479. doi: 10.3389/fchem.2021.746479.", "ArticleIdList": ["10.3389/fchem.2021.746479", "PMC8499677", "34631667"]}, {"Citation": "Burstein S.H., Menezes F., Williamson E., MECHOULAM R. Metabolism of \u03941 (6)-Tetrahydro-cannabinol, an active marihuana constituent. Nature. 1970;225:87\u201388. doi: 10.1038/225087a0.", "ArticleIdList": ["10.1038/225087a0", "5410211"]}, {"Citation": "Watanabe K., Yamaori S., Funahashi T., Kimura T., Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci. 2007;80:1415\u20131419. doi: 10.1016/j.lfs.2006.12.032.", "ArticleIdList": ["10.1016/j.lfs.2006.12.032", "17303175"]}, {"Citation": "Huestis M.A. Human cannabinoid pharmacokinetics. Chem. Biodivers. 2007;4:1770. doi: 10.1002/cbdv.200790152.", "ArticleIdList": ["10.1002/cbdv.200790152", "PMC2689518", "17712819"]}, {"Citation": "Tagen M., Klumpers L.E. Review of delta-8-tetrahydrocannabinol (\u03948-THC): Comparative pharmacology with \u03949-THC. Br. J. Pharmacol. 2022;179:3915\u20133933. doi: 10.1111/bph.15865.", "ArticleIdList": ["10.1111/bph.15865", "35523678"]}, {"Citation": "Watanabe K., Yamamoto I., Oguri K., Yoshimura H. Metabolic disposition of delta 8-tetrahydrocannabinol and its active metabolites, 11-hydroxy-delta 8-tetrahydrocannabinol and 11-oxo-delta 8-tetrahydrocannabinol, in mice. Drug Metab. Dispos. 1981;9:261\u2013264.", "ArticleIdList": ["6113937"]}, {"Citation": "Rosenthal J., Howell M., Earl V., Malik M. Cannabinoid hyperemesis syndrome secondary to delta-8 THC use. Am. J. Med. 2021;134:e582\u2013e583. doi: 10.1016/j.amjmed.2021.06.048.", "ArticleIdList": ["10.1016/j.amjmed.2021.06.048", "34343506"]}, {"Citation": "Helander A., Johansson M., Andersson A., Vill\u00e9n T. Analytical and medico-legal problems linked to the presence of delta-8-tetrahydrocannabinol (delta-8-THC): Results from urine drug testing in Sweden. Drug Test. Anal. 2022;14:371\u2013376. doi: 10.1002/dta.3190.", "ArticleIdList": ["10.1002/dta.3190", "34734479"]}, {"Citation": "Valiveti S., Hammell D.C., Earles D.C., Stinchcomb A.L. LC\u2013MS method for the estimation of \u03948-THC and 11-nor-\u03948-THC-9-COOH in plasma. J. Pharm. Biomed. Anal. 2005;38:112\u2013118. doi: 10.1016/j.jpba.2004.11.055.", "ArticleIdList": ["10.1016/j.jpba.2004.11.055", "15907628"]}, {"Citation": "Akpunonu P., Baum R.A., Reckers A., Davidson B., Ellison R., Riley M., Trecki J., Gerona R. Sedation and acute encephalopathy in a pediatric patient following ingestion of delta-8-tetrahydrocannabinol gummies. Am. J. Case Rep. 2021;22:e933488. doi: 10.12659/AJCR.933488.", "ArticleIdList": ["10.12659/AJCR.933488", "PMC8594112", "34762615"]}, {"Citation": "Vikingsson S., Hart E.D., Winecker R.E., Cone E.J., Kuntz D.J., Clark M., Jacques M., Hayes E.D., Flegel R.R. Prevalence of \u2206 8-tetrahydrocannabinol carboxylic acid in workplace drug testing. J. Anal. Toxicol. 2023;47:719\u2013725. doi: 10.1093/jat/bkad068.", "ArticleIdList": ["10.1093/jat/bkad068", "37697897"]}, {"Citation": "Sim Y.E., Kim J.W., Ko B.J., Kim J.Y., Cheong J.C., Pyo J. Determination of urinary metabolites of cannabidiol, \u03948-tetrahydrocannabinol, and \u03949-tetrahydrocannabinol by automated online \u03bcSPE\u2013LC\u2013MS/MS method. J. Chromatogr. B. 2023;1214:123568. doi: 10.1016/j.jchromb.2022.123568.", "ArticleIdList": ["10.1016/j.jchromb.2022.123568", "36527808"]}, {"Citation": "Lin L., Amaratunga P., Reed J., Huang P., Lemberg B.L., Lemberg D. Quantitation of \u03948-THC, \u03949-THC, cannabidiol and 10 other cannabinoids and metabolites in oral fluid by HPLC\u2013MS-MS. J. Anal. Toxicol. 2022;46:76\u201388. doi: 10.1093/jat/bkaa184.", "ArticleIdList": ["10.1093/jat/bkaa184", "33270860"]}, {"Citation": "Coulter C., Wagner J.R. Cannabinoids in oral fluid: Limiting potential sources of cannabidiol conversion to \u03949-and \u03948-tetrahydrocannabinol. J. Anal. Toxicol. 2021;45:807\u2013812. doi: 10.1093/jat/bkab074.", "ArticleIdList": ["10.1093/jat/bkab074", "34137890"]}, {"Citation": "Milman G., Barnes A.J., Schwope D.M., Schwilke E.W., Darwin W.D., Goodwin R.S., Kelly D.L., Gorelick D.A., Huestis M.A. Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. Clin. Chem. 2010;56:1261\u20131269. doi: 10.1373/clinchem.2009.141853.", "ArticleIdList": ["10.1373/clinchem.2009.141853", "PMC3171507", "20530732"]}, {"Citation": "H\u00e4dener M., K\u00f6nig S., Fabritius M.M., Weinmann W. Using THC-COOH cut-off concentrations for assessing cannabis consumption frequency: A recently detected THC-COOH isomer poses an important analytical problem. Toxichem. Krimtech. 2017;84:168."}, {"Citation": "Baird S.N., Frazee C.C., III, Garg U. Evaluation of a Delta-9-Tetrahydrocannabinol Carboxylic Acid (\u03949-THC-COOH) Immunoassay and a Gas Chromatography\u2013Mass Spectrometry (GC-MS) Method for the Detection of Delta-8-Tetrahydrocannabinol Carboxylic Acid (\u03948-THC-COOH) J. Appl. Lab. Med. 2023;8:665\u2013673. doi: 10.1093/jalm/jfad017.", "ArticleIdList": ["10.1093/jalm/jfad017", "37071885"]}, {"Citation": "Crosby M.M., Truver M.T., Chronister C.W., Hoyer J.L., Kinsey A.M., Brogan S.C., Goldberger B.A. Identification of 11-nor-\u2206 8-Tetrahydrocannabinol-9-Carboxylic Acid in Postmortem Urine. J. Anal. Toxicol. 2023;47:481\u2013487. doi: 10.1093/jat/bkad023.", "ArticleIdList": ["10.1093/jat/bkad023", "37026691"]}, {"Citation": "Pokhai A.A., Poklis J.L., Williams G.R., Wolf C.E. The preanalytical stability of emerging cannabinoid analogs (delta-8 THC and its metabolites, delta-10 THC and carboxy-HHC) in urine. J. Anal. Toxicol. 2023;47:726\u2013731. doi: 10.1093/jat/bkad061.", "ArticleIdList": ["10.1093/jat/bkad061", "37616492"]}, {"Citation": "Morin M.M., Baum M. Effects of delta8 tetrahydrocannabinol (THC) on avoidance extinction in rats. Bull. Psychon. Soc. 1986;24:385\u2013387. doi: 10.3758/BF03330161.", "ArticleIdList": ["10.3758/BF03330161"]}, {"Citation": "Christensen H., Freudenthal R., Gidley J., Rosenfeld R., Boegli G., Testino L., Brine D., Pitt C., Wall M. Activity of \u03948-and \u03949-tetrahydrocannabinol and related compounds in the mouse. Science. 1971;172:165\u2013167. doi: 10.1126/science.172.3979.165.", "ArticleIdList": ["10.1126/science.172.3979.165", "5547729"]}, {"Citation": "Mackie K. Cannabinoid receptors: Where they are and what they do. J. Neuroendocrinol. 2008;20((Suppl. S1)):10\u201314. doi: 10.1111/j.1365-2826.2008.01671.x.", "ArticleIdList": ["10.1111/j.1365-2826.2008.01671.x", "18426493"]}, {"Citation": "Pertwee R.G., Ross R. Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fat. Acids (PLEFA) 2002;66:101\u2013121. doi: 10.1054/plef.2001.0341.", "ArticleIdList": ["10.1054/plef.2001.0341", "12052030"]}, {"Citation": "Howlett A.C. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 2002;68\u201369:619\u2013631. doi: 10.1016/S0090-6980(02)00060-6.", "ArticleIdList": ["10.1016/S0090-6980(02)00060-6", "12432948"]}, {"Citation": "Mechoulam R., Parker L.A. The endocannabinoid system and the brain. Annu. Rev. Psychol. 2013;64:21\u201347. doi: 10.1146/annurev-psych-113011-143739.", "ArticleIdList": ["10.1146/annurev-psych-113011-143739", "22804774"]}, {"Citation": "Govaerts S.J., Hermans E., Lambert D.M. Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. Eur. J. Pharm. Sci. 2004;23:233\u2013243. doi: 10.1016/j.ejps.2004.07.013.", "ArticleIdList": ["10.1016/j.ejps.2004.07.013", "15489124"]}, {"Citation": "Nadipuram A.K., Krishnamurthy M., Ferreira A.M., Li W., Moore II B.M. Synthesis and testing of novel classical cannabinoids: Exploring the side chain ligand binding pocket of the CB1 and CB2 receptors. Bioorganic Med. Chem. 2003;11:3121\u20133132. doi: 10.1016/S0968-0896(03)00238-4.", "ArticleIdList": ["10.1016/S0968-0896(03)00238-4", "12818675"]}, {"Citation": "Huffman J.W., Liddle J., Yu S., Aung M.M., Abood M.E., Wiley J.L., Martin B.R. 3-(1\u2032,1\u2032-Dimethylbutyl)-1-deoxy-\u03948-THC and related compounds: Synthesis of selective ligands for the CB2 receptor. Bioorganic Med. Chem. 1999;7:2905\u20132914. doi: 10.1016/S0968-0896(99)00219-9.", "ArticleIdList": ["10.1016/S0968-0896(99)00219-9", "10658595"]}, {"Citation": "Hirst R.A., Almond S.L., Lambert D.G. Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist. Neurosci. Lett. 1996;220:101\u2013104. doi: 10.1016/S0304-3940(96)13233-X.", "ArticleIdList": ["10.1016/S0304-3940(96)13233-X", "8981483"]}, {"Citation": "Martin B.R., Compton D.R., Semus S.F., Lin S., Marciniak G., Grzybowska J., Charalambous A., Makriyannis A. Pharmacological evaluation of iodo and nitro analogs of \u03948-THC and \u03949-THC. Pharmacol. Biochem. Behav. 1993;46:295\u2013301. doi: 10.1016/0091-3057(93)90356-X.", "ArticleIdList": ["10.1016/0091-3057(93)90356-X", "8265683"]}, {"Citation": "Huffman J.W., Miller J.R., Liddle J., Yu S., Thomas B.F., Wiley J.L., Martin B.R. Structure\u2013activity relationships for 1\u2032,1\u2032-dimethylalkyl-\u03948-tetrahydrocannabinols. Bioorganic Med. Chem. 2003;11:1397\u20131410. doi: 10.1016/S0968-0896(02)00649-1.", "ArticleIdList": ["10.1016/S0968-0896(02)00649-1", "12628666"]}, {"Citation": "Busch-Petersen J., Hill W.A., Fan P., Khanolkar A., Xie X.-Q., Tius M.A., Makriyannis A. Unsaturated side chain \u03b2-11-hydroxyhexahydrocannabinol analogs. J. Med. Chem. 1996;39:3790\u20133796. doi: 10.1021/jm950934b.", "ArticleIdList": ["10.1021/jm950934b", "8809166"]}, {"Citation": "Charalambous A., Lin S., Marciniak G., Banijamali A., Friend F., Compton D., Martin B., Makriyannis A. Pharmacological evaluation of halogenated \u03948-THC analogs. Pharmacol. Biochem. Behav. 1991;40:509\u2013512. doi: 10.1016/0091-3057(91)90355-6.", "ArticleIdList": ["10.1016/0091-3057(91)90355-6", "1666915"]}, {"Citation": "Papahatjis D.P., Nahmias V.R., Andreou T., Fan P., Makriyannis A. Structural modifications of the cannabinoid side chain towards C3-aryl and 1\u2032,1\u2032-cycloalkyl-1\u2032-cyano cannabinoids. Bioorganic Med. Chem. Lett. 2006;16:1616\u20131620. doi: 10.1016/j.bmcl.2005.12.026.", "ArticleIdList": ["10.1016/j.bmcl.2005.12.026", "16387492"]}, {"Citation": "Darmani N.A., Janoyan J.J., Crim J., Ramirez J. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew. Eur. J. Pharmacol. 2007;563:187\u2013196. doi: 10.1016/j.ejphar.2007.01.093.", "ArticleIdList": ["10.1016/j.ejphar.2007.01.093", "PMC1949344", "17362921"]}, {"Citation": "G\u00e9rard C.M., Mollereau C., Vassart G., Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Pt 1Biochem. J. 1991;279:129\u2013134. doi: 10.1042/bj2790129.", "ArticleIdList": ["10.1042/bj2790129", "PMC1151556", "1718258"]}, {"Citation": "Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561\u2013564. doi: 10.1038/346561a0.", "ArticleIdList": ["10.1038/346561a0", "2165569"]}, {"Citation": "Little P.J., Martin B.R. The effects of delta 9-tetrahydrocannabinol and other cannabinoids on cAMP accumulation in synaptosomes. Life Sci. 1991;48:1133\u20131141. doi: 10.1016/0024-3205(91)90450-P.", "ArticleIdList": ["10.1016/0024-3205(91)90450-P", "1848340"]}, {"Citation": "Domino E.F. Cannabinoids and the cholinergic system. J. Clin. Pharmacol. 1981;21:249S\u2013255S. doi: 10.1002/j.1552-4604.1981.tb02602.x.", "ArticleIdList": ["10.1002/j.1552-4604.1981.tb02602.x", "6271830"]}, {"Citation": "Tripathi H., Vocci F., Brase D., Dewey W. Effects of cannabinoids on levels of acetylcholine and choline and on turnover rate of acetylcholine in various regions of the mouse brain. Alcohol Drug Res. 1987;7:525\u2013532.", "ArticleIdList": ["3620017"]}, {"Citation": "Clarke D., Jandhyala B. Acute and chronic effects of tetrahydrocannabinols on monoamide oxidase activity: Possible vehicle/tetrahydrocannabinol interactions. Res. Commun. Chem. Pathol. Pharmacol. 1977;17:471\u2013480.", "ArticleIdList": ["897340"]}, {"Citation": "Avraham Y., Ben-Shushan D., Breuer A., Zolotarev O., Okon A., Fink N., Katz V., Berry E.M. Very low doses of \u03948-THC increase food consumption and alter neurotransmitter levels following weight loss. Pharmacol. Biochem. Behav. 2004;77:675\u2013684. doi: 10.1016/j.pbb.2004.01.015.", "ArticleIdList": ["10.1016/j.pbb.2004.01.015", "15099912"]}, {"Citation": "Darmani N.A. Cannabinoids of diverse structure inhibit two DOI-induced 5-HT2A receptor-mediated behaviors in mice. Pharmacol. Biochem. Behav. 2001;68:311\u2013317. doi: 10.1016/S0091-3057(00)00477-9.", "ArticleIdList": ["10.1016/S0091-3057(00)00477-9", "11267636"]}, {"Citation": "MacLean K.I., Littleton J.M. Environmental stress as a factor in the response of rat brain catecholamine metabolism to \u03948-tetrahydrocannabinol. Eur. J. Pharmacol. 1977;41:171\u2013182. doi: 10.1016/0014-2999(77)90206-0.", "ArticleIdList": ["10.1016/0014-2999(77)90206-0", "832673"]}, {"Citation": "Poddar M., Dewey W. Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J. Pharmacol. Exp. Ther. 1980;214:63\u201367.", "ArticleIdList": ["7391971"]}, {"Citation": "Sagratella S., de Carolis A.S., Longo V. EEG interaction between delta 8-tetrahydrocannabinol and some sedative-anxiolytic drugs. Is the anxiogenic effect of cannabis related to an action on the GABAergic system? Adv. Biochem. Psychopharmacol. 1986;41:203\u2013209.", "ArticleIdList": ["3017070"]}, {"Citation": "J\u00c4rbe T.U., Henriksson B.G. Effects of \u03948-THC, and \u03949-THC on the acquisition of a discriminative positional habit in rats: The transitions between normal and tetrahydrocannabinol-induced states on reversal learning. Psychopharmacologia. 1973;31:321\u2013332. doi: 10.1007/BF00421276.", "ArticleIdList": ["10.1007/BF00421276", "4795349"]}, {"Citation": "J\u00e4rbe T., Johansson J., Henriksson B. Characteristics of tetrahydrocannabinol (THC)-produced discrimination in rats. Psychopharmacology. 1976;48:181\u2013187. doi: 10.1007/BF00423258.", "ArticleIdList": ["10.1007/BF00423258", "137414"]}, {"Citation": "J\u00c4rbe T.U., Henriksson B.G. Discriminative response control produced with hashish, tetrahydrocannabinols (\u03948-THC and \u03949-THC), and other drugs. Psychopharmacologia. 1974;40:1\u201316. doi: 10.1007/BF00429443.", "ArticleIdList": ["10.1007/BF00429443", "4445444"]}, {"Citation": "Bueno O., Carlini E., Finkelfarb E., Suzuki J.S. \u03949-Tetrahydrocannabinol, ethanol, and amphetamine as discriminative stimuli-generalization tests with other drugs. Psychopharmacologia. 1976;46:235\u2013243. doi: 10.1007/BF00421108.", "ArticleIdList": ["10.1007/BF00421108", "951459"]}, {"Citation": "Doty P., Dykstra L.A., Picker M.J. Discriminative stimulus effects of phencyclidine: Pharmacologically specific interactions with \u03949-and \u03948-tetrahydrocannabinol. Drug Alcohol Depend. 1994;35:151\u2013158. doi: 10.1016/0376-8716(94)90122-8.", "ArticleIdList": ["10.1016/0376-8716(94)90122-8", "8055736"]}, {"Citation": "J\u00e4rbe T.U., Henriksson B.G., Ohlin G.C. Delta9-THC as a discriminative cue in pigeons: Effects of delta8-THC, CBD, and CBN. Arch. Int. Pharmacodyn. Ther. 1977;228:68\u201372.", "ArticleIdList": ["921403"]}, {"Citation": "Hine B., Torrelio M., Gershon S. Analgesic, heart rate, and temperature effects of \u03948-THC during acute and chronic administration to conscious rats. Pharmacology. 1977;15:65\u201372. doi: 10.1159/000136664.", "ArticleIdList": ["10.1159/000136664", "14347"]}, {"Citation": "Durbin D.J., King J.M., Stairs D.J. Behavioral Effects of Vaporized Delta-8 Tetrahydrocannabinol, Cannabidiol, and Mixtures in Male Rats. Cannabis Cannabinoid Res. 2023 doi: 10.1089/can.2022.0257. ahead of print .", "ArticleIdList": ["10.1089/can.2022.0257", "36802211"]}, {"Citation": "Chesher G., Dahl C., Everingham M., Jackson D., Marchant-Williams H., Starmer G. The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice. Br. J. Pharmacol. 1973;49:588\u2013594. doi: 10.1111/j.1476-5381.1973.tb08534.x.", "ArticleIdList": ["10.1111/j.1476-5381.1973.tb08534.x", "PMC1776598", "4788032"]}, {"Citation": "Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. 1992;262:10\u201318.", "ArticleIdList": ["1320680"]}, {"Citation": "Welch S.P., Thomas C., Patrick G.S. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: Possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 1995;272:310\u2013321.", "ArticleIdList": ["7815346"]}, {"Citation": "El-Alfy A.T., Ivey K., Robinson K., Ahmed S., Radwan M., Slade D., Khan I., ElSohly M., Ross S. Antidepressant-like effect of \u03949-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol. Biochem. Behav. 2010;95:434\u2013442. doi: 10.1016/j.pbb.2010.03.004.", "ArticleIdList": ["10.1016/j.pbb.2010.03.004", "PMC2866040", "20332000"]}, {"Citation": "Welch S.P., Huffman J.W., Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J. Pharmacol. Exp. Ther. 1998;286:1301\u20131308.", "ArticleIdList": ["9732392"]}, {"Citation": "Consroe P.F., Man D.P., Chin L., Picchioni A.L. Reduction of audiogenic seizure by \u03948-and \u03949-tetrahydrocannabinols. J. Pharm. Pharmacol. 1973;25:764\u2013765. doi: 10.1111/j.2042-7158.1973.tb10067.x.", "ArticleIdList": ["10.1111/j.2042-7158.1973.tb10067.x", "4148520"]}, {"Citation": "Corcoran M.E., McCaughran J.A., Jr., Wada J.A. Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled rats. Epilepsia. 1978;19:47\u201355. doi: 10.1111/j.1528-1157.1978.tb05011.x.", "ArticleIdList": ["10.1111/j.1528-1157.1978.tb05011.x", "624268"]}, {"Citation": "Wada J.A., Osawa T., Corcoran M.E. Effects of tetrahydrocannabinols on kindled amygdaloid seizures and photogenic seizures in Senegalese baboons, Papio papio. Epilepsia. 1975;16:439\u2013448. doi: 10.1111/j.1528-1157.1975.tb06071.x.", "ArticleIdList": ["10.1111/j.1528-1157.1975.tb06071.x", "810346"]}, {"Citation": "Wada J.A., Wake A., Sato M., Corcoran M.E. Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled cats. Epilepsia. 1975;16:503\u2013510. doi: 10.1111/j.1528-1157.1975.tb06080.x.", "ArticleIdList": ["10.1111/j.1528-1157.1975.tb06080.x", "1183427"]}, {"Citation": "Brenda K.C., Charles L., Charles R.C. Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats. Pharmacol. Biochem. Behav. 1982;16:573\u2013578.", "ArticleIdList": ["6280204"]}, {"Citation": "Chandradhar D., Raymond D.H. Anticonvulsant activities of \u0394-8 and \u0394-9 tetrahydrocanabinol and uridine. Toxicol. Appl. Pharmacol. 1975;31:452\u2013458.", "ArticleIdList": ["1145630"]}, {"Citation": "Johansson J., Jarbe T., Henriksson B. Acute and subchronic influences of tetrahydrocannabinols on water and food intake, body weight, and temperature in rats. T.-I.-T. J. Life Sci. 1975;5:17\u201327.", "ArticleIdList": ["1188935"]}, {"Citation": "Smiley K., Karler R., Turkanis S. Effects of cannabinoids on the perfused rat heart. Res. Commun. Chem. Pathol. Pharmacol. 1976;14:659\u2013675.", "ArticleIdList": ["959665"]}, {"Citation": "Coffey R.G., Yamamoto Y., Snella E., Pross S. Tetrahydrocannabinol inhibition of macrophage nitric oxide production. Biochem. Pharmacol. 1996;52:743\u2013751. doi: 10.1016/0006-2952(96)00356-5.", "ArticleIdList": ["10.1016/0006-2952(96)00356-5", "8765472"]}, {"Citation": "Adams M., Earnhardt J., Dewey W., Harris L. Vasoconstrictor actions of delta8-and delta9-tetrahydrocannabinol in the rat. J. Pharmacol. Exp. Ther. 1976;196:649\u2013656.", "ArticleIdList": ["4606"]}, {"Citation": "Abrahamov A., Abrahamov A., Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 1995;56:2097\u20132102. doi: 10.1016/0024-3205(95)00194-B.", "ArticleIdList": ["10.1016/0024-3205(95)00194-B", "7776837"]}, {"Citation": "Carchman R.A., Harris L.S., Munson A.E. The inhibition of DNA synthesis by cannabinoids. Cancer Res. 1976;36:95\u2013100.", "ArticleIdList": ["1248011"]}, {"Citation": "Tucker A.N., Friedman M.A. Effects of cannabinoids on L1210 murine leukemia. 1. Inhibition of DNA synthesis. Res. Commun. Chem. Pathol. Pharmacol. 1977;17:703\u2013714.", "ArticleIdList": ["897352"]}, {"Citation": "Tucker A.N., Friedman M.A. Effects of cannabinoids on L1210 murine leukemia. III. Inhibition of respiration. Res. Commun. Chem. Pathol. Pharmacol. 1979;23:327\u2013332.", "ArticleIdList": ["461956"]}, {"Citation": "Green L.G., Stein J.L., Stein G.S. A decreased influence of cannabinoids on macromolecular biosynthesis and cell proliferation in human cells which metabolize polycyclic hydrocarbon carcinogens. Anticancer Res. 1983;3:211\u2013217.", "ArticleIdList": ["6191620"]}, {"Citation": "Howlett A.C., Fleming R.M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol. 1984;26:532\u2013538.", "ArticleIdList": ["6092901"]}, {"Citation": "Moln\u00e1r J., Szab\u00f3 D., Pusztai R., Mucsi I., Berek L., Ocsovszki I., Kawata E., Shoyama Y. Membrane associated antitumor effects of crocine-, ginsenoside- and cannabinoid derivates. Anticancer Res. 2000;20:861\u2013867.", "ArticleIdList": ["10810367"]}, {"Citation": "Whyte D.A., Al-Hammadi S., Balhaj G., Brown O.M., Penefsky H.S., Souid A.K. Cannabinoids inhibit cellular respiration of human oral cancer cells. Pharmacology. 2010;85:328\u2013335. doi: 10.1159/000312686.", "ArticleIdList": ["10.1159/000312686", "20516734"]}, {"Citation": "Semlali A., Beji S., Ajala I., Rouabhia M. Effects of tetrahydrocannabinols on human oral cancer cell proliferation, apoptosis, autophagy, oxidative stress, and DNA damage. Arch. Oral Biol. 2021;129:105200. doi: 10.1016/j.archoralbio.2021.105200.", "ArticleIdList": ["10.1016/j.archoralbio.2021.105200", "34146926"]}, {"Citation": "Munson A.E., Harris L.S., Friedman M.A., Dewey W.L., Carchman R.A. Antineoplastic Activity of Cannabinoids2. JNCI J. Natl. Cancer Inst. 1975;55:597\u2013602. doi: 10.1093/jnci/55.3.597.", "ArticleIdList": ["10.1093/jnci/55.3.597", "1159836"]}, {"Citation": "Friedman M.A. In vivo effects of cannabinoids on macromolecular biosynthesis in Lewis lung carcinomas. Cancer Biochem. Biophys. 1977;2:51\u201354.", "ArticleIdList": ["616322"]}, {"Citation": "Nahas G.G., Morishima A., Desoize B. Effects of cannabinoids on macromolecular synthesis and replication of cultured lymphocytes. Fed. Proc. 1977;36:1748\u20131752.", "ArticleIdList": ["844617"]}, {"Citation": "Schwarz H., Blanco F.J., Lotz M. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmunol. 1994;55:107\u2013115. doi: 10.1016/0165-5728(94)90152-X.", "ArticleIdList": ["10.1016/0165-5728(94)90152-X", "7962480"]}, {"Citation": "Yamaori S., Ishii H., Chiba K., Yamamoto I., Watanabe K. \u03948-Tetrahydrocannabinol induces cytotoxicity in macrophage J774-1 cells: Involvement of cannabinoid receptor 2 and p38 MAPK. Toxicology. 2013;314:254\u2013261. doi: 10.1016/j.tox.2013.10.007.", "ArticleIdList": ["10.1016/j.tox.2013.10.007", "24184660"]}, {"Citation": "Loveless S., Harris L., Munson A. Hyporesponsiveness to the immunosuppressant effects of delta-8-tetrahydrocannabinol. J. Immunopharmacol. 1981;3:371\u2013384. doi: 10.3109/08923978109031068.", "ArticleIdList": ["10.3109/08923978109031068", "6290570"]}, {"Citation": "Watson E.S., Murphy J.C., Turner C.E. Allergenic properties of naturally occurring cannabinoids. J. Pharm. Sci. 1983;72:954\u2013955. doi: 10.1002/jps.2600720831.", "ArticleIdList": ["10.1002/jps.2600720831", "6620158"]}, {"Citation": "Wirguin I., Mechoulam R., Breuer A., Schezen E., Weidenfeld J., Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology. 1994;28:209\u2013214. doi: 10.1016/0162-3109(94)90056-6.", "ArticleIdList": ["10.1016/0162-3109(94)90056-6", "7852052"]}, {"Citation": "Yamaguchi T., Shoyama Y., Watanabe S., Yamamoto T. Behavioral suppression induced by cannabinoids is due to activation of the arachidonic acid cascade in rats. Brain Res. 2001;889:149\u2013154. doi: 10.1016/S0006-8993(00)03127-9.", "ArticleIdList": ["10.1016/S0006-8993(00)03127-9", "11166698"]}, {"Citation": "Yamaguchi T., Kubota T., Watanabe S., Yamamoto T. Activation of brain prostanoid EP3 receptors via arachidonic acid cascade during behavioral suppression induced by Delta8-tetrahydrocannabinol. J. Neurochem. 2004;88:148\u2013154. doi: 10.1046/j.1471-4159.2003.02151.x.", "ArticleIdList": ["10.1046/j.1471-4159.2003.02151.x", "14675158"]}, {"Citation": "Chen Y., Buck J. Cannabinoids protect cells from oxidative cell death: A receptor-independent mechanism. J. Pharmacol. Exp. Ther. 2000;293:807\u2013812.", "ArticleIdList": ["10869379"]}, {"Citation": "Thapa D., Cairns E.A., Szczesniak A.-M., Toguri J.T., Caldwell M.D., Kelly M.E. The cannabinoids \u03948THC, CBD, and HU-308 act via distinct receptors to reduce corneal pain and inflammation. Cannabis Cannabinoid Res. 2018;3:11\u201320. doi: 10.1089/can.2017.0041.", "ArticleIdList": ["10.1089/can.2017.0041", "PMC5812319", "29450258"]}, {"Citation": "Punyamurthula N.S., Adelli G.R., Gul W., Repka M.A., ElSohly M.A., Majumdar S. Ocular disposition of\u2206 8-tetrahydrocannabinol from various topical ophthalmic formulations. AAPS PharmSciTech. 2017;18:1936\u20131945. doi: 10.1208/s12249-016-0672-2.", "ArticleIdList": ["10.1208/s12249-016-0672-2", "PMC5629008", "27905004"]}, {"Citation": "Muchtar S., Almog S., Torracca M., Saettone M., Benita S. A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: Effect on intraocular pressure in rabbits. Ophthalmic Res. 1992;24:142\u2013149. doi: 10.1159/000267160.", "ArticleIdList": ["10.1159/000267160", "1328979"]}, {"Citation": "Elsohly M., Harland E., Murphy J., Wirth P., Waller C. Cannabinoids in glaucoma: A primary screening procedure. J. Clin. Pharmacol. 1981;21:472S\u2013478S. doi: 10.1002/j.1552-4604.1981.tb02627.x.", "ArticleIdList": ["10.1002/j.1552-4604.1981.tb02627.x", "6271842"]}, {"Citation": "Elsohly M.A., Harland E.C., Benigni D.A., Waller C.W. Cannabinoids in glaucoma II: The effect of different cannabinoids on intraocular pressure of the rabbit. Curr. Eye Res. 1984;3:841\u2013850. doi: 10.3109/02713688409000797.", "ArticleIdList": ["10.3109/02713688409000797", "6329602"]}, {"Citation": "Green K., Symonds C.M., Oliver N.W., Elijah R.D. Intraocular pressure following systemic administration of cannabinoids. Curr. Eye Res. 1982;2:247\u2013253. doi: 10.3109/02713688209011626.", "ArticleIdList": ["10.3109/02713688209011626", "6295702"]}, {"Citation": "Badawy Z.S., Chohan K.R., Whyte D.A., Penefsky H.S., Brown O.M., Souid A.-K. Cannabinoids inhibit the respiration of human sperm. Fertil. Steril. 2009;91:2471\u20132476. doi: 10.1016/j.fertnstert.2008.03.075.", "ArticleIdList": ["10.1016/j.fertnstert.2008.03.075", "18565513"]}, {"Citation": "Gupta D., Elbracht C. Effect of tetrahydrocannabinols on pubertal body weight spurt and sex hormones in developing male rats. Res. Exp. Med. 1983;182:95\u2013104. doi: 10.1007/BF01851115.", "ArticleIdList": ["10.1007/BF01851115", "6306747"]}, {"Citation": "Knopf A. CDC and FDA warn of delta-8 THC harms. Alcohol. Drug Abus. Wkly. 2021;33:7. doi: 10.1002/adaw.33199.", "ArticleIdList": ["10.1002/adaw.33199"]}, {"Citation": "Erickson B.E. Delta-8-THC craze concerns chemists. Chem. Eng. News. 2021;99:25\u201328."}, {"Citation": "Leas E.C., Harati R.M., Satybaldiyeva N., Morales N.E., Huffaker S.L., Mejorado T., Grant I. Self-reported adverse events associated with\u2206 8-Tetrahydrocannabinol (Delta-8-THC) Use. J. Cannabis Res. 2023;5:15. doi: 10.1186/s42238-023-00191-y.", "ArticleIdList": ["10.1186/s42238-023-00191-y", "PMC10204335", "37217977"]}, {"Citation": "Johnson M.J., Swenson C., Fishkin I., Malanga A. Now I know my CBDs; cases of psychiatric admissions after delta-8-tetrahydrocannabinol (delta-8-THC, \u03948-THC) product usage. Psychiatry Res. Case Rep. 2023;2:100166. doi: 10.1016/j.psycr.2023.100166.", "ArticleIdList": ["10.1016/j.psycr.2023.100166"]}, {"Citation": "Shaker K., Nillas A., Ellison R., Martin K., Trecki J., Gerona R., Aldy K. Delta-8-tetrahydrocannabinol exposure and confirmation in four pediatric patients. J. Med. Toxicol. 2023;19:190\u2013195. doi: 10.1007/s13181-022-00927-x.", "ArticleIdList": ["10.1007/s13181-022-00927-x", "PMC10050257", "36757578"]}, {"Citation": "Wrenn J., Friedman M. Effects of chronic administration of delta8-and delta9-tetrahydro-cannabinol on hepatic tyrosine aminotransferase activity in mice. Arch. Int. Pharmacodyn. Ther. 1978;235:4\u20138.", "ArticleIdList": ["32853"]}, {"Citation": "Bozman M.E., Manoharan S.V.R.R., Vasavada T. Marijuana variant of concern: Delta 8-tetrahydrocannabinol (delta-8-THC, \u03948-THC) Psychiatry Res. Case Rep. 2022;1:100028. doi: 10.1016/j.psycr.2022.100028.", "ArticleIdList": ["10.1016/j.psycr.2022.100028"]}, {"Citation": "Watanabe K., Narimatsu S., Yamamoto I., Yoshimura H. Difference in tolerance development to hypothermia and pentobarbital-induced sleep prolongating effect of 11-hydroxy-\u03948-tetrahydrocannabinol and 11-oxo-\u03948-tetrahydrocannabinol in mice. Eur. J. Pharmacol. 1982;77:53\u201356. doi: 10.1016/0014-2999(82)90535-0.", "ArticleIdList": ["10.1016/0014-2999(82)90535-0", "6277654"]}, {"Citation": "Watanabe K., Yamamoto I., Yoshimura H. Development of tolerance and cross-tolerance to the cataleptogenic effects of \u03948-tetrahydrocannabinol and 11-hydroxy-\u03948-tetrahydrocannabinol in mice. Eur. J. Pharmacol. 1983;94:349\u2013351. doi: 10.1016/0014-2999(83)90427-2.", "ArticleIdList": ["10.1016/0014-2999(83)90427-2", "6317407"]}, {"Citation": "Yamamoto I., Watanabe K., Narimatsu S., Hamajima K., Yoshimura H. Cross-tolerance to the hypothermic effect of \u03948-tetrahydrocannabinol 11-hydroxy-\u03948-tetrahydrocannabinol and chlorpromazine in the mouse. Eur. J. Pharmacol. 1985;111:159\u2013166. doi: 10.1016/0014-2999(85)90752-6.", "ArticleIdList": ["10.1016/0014-2999(85)90752-6", "2990949"]}, {"Citation": "Narimatsu S., Yamamoto I., Watanabe K., Yoshimura H. Change in hypothermia and catalepsy induced by cannabinoids or morphine in mice tolerant to these substances. Eur. J. Pharmacol. 1987;141:437\u2013443. doi: 10.1016/0014-2999(87)90562-0.", "ArticleIdList": ["10.1016/0014-2999(87)90562-0", "3666037"]}, {"Citation": "Yamaguchi T., Hagiwara Y., Tanaka H., Sugiura T., Waku K., Shoyama Y., Watanabe S., Yamamoto T. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res. 2001;909:121\u2013126. doi: 10.1016/S0006-8993(01)02655-5.", "ArticleIdList": ["10.1016/S0006-8993(01)02655-5", "11478928"]}, {"Citation": "Sj\u00f6d\u00e9n P.-O., J\u00e4rbe T.U., Henriksson B.G. Effects of long-term administration and withdrawal of tetrahydrocannabinols (\u03948-THC and \u03949-THC) on open-field behavior in rats. Pharmacol. Biochem. Behav. 1973;1:243\u2013249. doi: 10.1016/0091-3057(73)90111-1.", "ArticleIdList": ["10.1016/0091-3057(73)90111-1", "4798094"]}, {"Citation": "Bhargava H.N. Time course of the effects of naturally occurring cannabinoids on morphine abstinence syndrome. Pharmacol. Biochem. Behav. 1978;8:7\u201311. doi: 10.1016/0091-3057(78)90115-6.", "ArticleIdList": ["10.1016/0091-3057(78)90115-6", "564515"]}, {"Citation": "Nakamura-Palacios E.M., Bueno O.F.A., Takahashi R.N., Tufik S. Acute or chronic effects of cannabinoids on spontaneous or pharmacologically induced yawning in rats. Pharmacol. Biochem. Behav. 2002;74:205\u2013212. doi: 10.1016/S0091-3057(02)00991-7.", "ArticleIdList": ["10.1016/S0091-3057(02)00991-7", "12376169"]}, {"Citation": "Anggadiredja K., Yamaguchi T., Tanaka H., Shoyama Y., Watanabe S., Yamamoto T. Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal: A quasi abstinence approach. Brain Res. 2005;1066:201\u2013205. doi: 10.1016/j.brainres.2005.10.065.", "ArticleIdList": ["10.1016/j.brainres.2005.10.065", "16336946"]}, {"Citation": "Weinstein A.M., Gorelick D.A. Pharmacological treatment of cannabis dependence. Curr. Pharm. Des. 2011;17:1351\u20131358. doi: 10.2174/138161211796150846.", "ArticleIdList": ["10.2174/138161211796150846", "PMC3171994", "21524266"]}, {"Citation": "Connor J.P., Stjepanovi\u0107 D., Budney A.J., Le Foll B., Hall W.D. Clinical management of cannabis withdrawal. Addiction. 2022;117:2075\u20132095. doi: 10.1111/add.15743.", "ArticleIdList": ["10.1111/add.15743", "PMC9110555", "34791767"]}, {"Citation": "De Aquino J.P., Bahji A., G\u00f3mez O., Sofuoglu M. Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. Drug Alcohol Depend. 2022;241:109702. doi: 10.1016/j.drugalcdep.2022.109702.", "ArticleIdList": ["10.1016/j.drugalcdep.2022.109702", "PMC9772106", "36434879"]}, {"Citation": "McRae-Clark A.L., Baker N.L., Gray K.M., Killeen T.K., Wagner A.M., Brady K.T., DeVane C.L., Norton J. Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend. 2015;156:29\u201337. doi: 10.1016/j.drugalcdep.2015.08.013.", "ArticleIdList": ["10.1016/j.drugalcdep.2015.08.013", "PMC4633378", "26386827"]}, {"Citation": "Allsop D.J., Copeland J., Lintzeris N., Dunlop A.J., Montebello M., Sadler C., Rivas G.R., Holland R.M., Muhleisen P., Norberg M.M., et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: A randomized clinical trial. JAMA Psychiatry. 2014;71:281\u2013291. doi: 10.1001/jamapsychiatry.2013.3947.", "ArticleIdList": ["10.1001/jamapsychiatry.2013.3947", "24430917"]}, {"Citation": "Levin F.R., Kleber H.D. Use of Dronabinol for Cannabis Dependence: Two Case Reports and Review. Am. J. Addict. 2008;17:161\u2013164. doi: 10.1080/10550490701861177.", "ArticleIdList": ["10.1080/10550490701861177", "PMC2733248", "18393061"]}, {"Citation": "Bonnet U., Preuss U.W. The cannabis withdrawal syndrome: Current insights. Subst. Abus. Rehabil. 2017;8:9\u201337. doi: 10.2147/SAR.S109576.", "ArticleIdList": ["10.2147/SAR.S109576", "PMC5414724", "28490916"]}]}], "History": [{"Year": "2024", "Month": "2", "Day": "12"}, {"Year": "2024", "Month": "3", "Day": "6"}, {"Year": "2024", "Month": "3", "Day": "7"}, {"Year": "2024", "Month": "3", "Day": "29", "Hour": "6", "Minute": "46"}, {"Year": "2024", "Month": "3", "Day": "28", "Hour": "6", "Minute": "45"}, {"Year": "2024", "Month": "3", "Day": "28", "Hour": "1", "Minute": "22"}, {"Year": "2024", "Month": "3", "Day": "11"}], "PublicationStatus": "epublish", "ArticleIdList": ["38542886", "PMC10976172", "10.3390/molecules29061249", "molecules29061249"]}}]}